思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 即将召开： 2025年7月17日，第二届全球医疗科技大会 2025年9月3-5日，第三届全球手术机器人大会 2025年6月，海南证监局正式受理 百迈科北交所上市辅导备案材料 ，同意辅导备案， 百迈科正式开启IPO 。 | | | | 辅导对象 | 海南百迈科医疗科技股份有限公司 | | | | --- | --- | --- | --- | | 成立日期 | 2007-06-01 | | | | 注册资本 | 4,065.00万元 | 法定代表人 | 杨顶建 | | 注册地址 | 海南省定安县定城镇见龙社区环城南三环路18号 | | | | 控股股东 及持股比 | 控股股东为海南迈迪科医药控股有限公司,持股比例为 48.35% | | | | 倒 | | | | | 行业分类 | C27 医药制造业 | 在其他交易场 所(申请)挂 脾或上市的情 | 新三板挂牌(股票简 称:自迈科;股票代 码: 874640) | | | | 况 | | | 各 注 | 无 | | | # 财务数据 2024年，百迈科 ...

Company Overview - Hainan Baimaike Medical Technology Co., Ltd. (Baimaike) is a high-tech enterprise established on June 1, 2007, specializing in the research, production, and sales of surgical medical devices and peptide pharmaceutical equipment [1] - The company is planning to go public on the Beijing Stock Exchange with the guidance of Changcheng Securities [1] Financial Performance - In 2024, Baimaike achieved an operating income of 185 million yuan, representing a year-on-year growth of 6.27% [2][3] - The net profit attributable to shareholders decreased by 1.41% to approximately 69.19 million yuan [2][3] - The gross profit margin improved to 78.8%, up from 75.88% in the previous year [2][3] Shareholding Structure - The controlling shareholder is Hainan Maidike Pharmaceutical Holdings Co., Ltd., holding 48.35% of the shares [1][3] - Yang Dingjian, the actual controller, directly holds 2.98 million shares (7.33% of total shares) and indirectly controls 60.99% of the voting rights through various entities [4][6] Leadership Background - Yang Dingjian, born in October 1972, holds a Ph.D. in Biochemistry and Molecular Biology from Lanzhou University and has extensive experience in the pharmaceutical industry [6][7] - He has held various leadership positions, including General Manager of Hainan Zhonghe Pharmaceutical Co., Ltd. and Chairman of Baimaike since June 2022 [6][7]